1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction
(
- Contribution to journal › Article
- 2017
-
Mark
Diabetic patients with acute coronary syndromes in contemporary European registries : Characteristics and outcomes
(
- Contribution to journal › Article
- 2016
-
Mark
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly : results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients
(
- Contribution to journal › Article
-
Mark
P2Y12 receptor inhibitors in patients with non-STelevation acute coronary syndrome in the real world : Use, patient selection, and outcomes from contemporary European registries
(
- Contribution to journal › Article
-
Mark
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries
(
- Contribution to journal › Article
- 2015
-
Mark
Improving outcomes in patients with coronary heart disease using national registers and platelet function testing
(
- Thesis › Doctoral thesis (compilation)
- 2014
-
Mark
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
(
- Contribution to journal › Article
- 2012
-
Mark
Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER Trial.
(
- Contribution to journal › Article
- 2009
-
Mark
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article